Steiner, T. J.
Jensen, R.
Katsarava, Z.
Linde, M.
MacGregor, E. A.
Osipova, V.
Paemeleire, K.
Olesen, J.
Peters, M.
Martelletti, P.
Article History
Received: 20 January 2018
Accepted: 31 July 2018
First Online: 21 May 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: TJS, ML, EAM, JO and MP declare no conflicts of interest. RJ has received honoraria as a speaker and/or conducted clinical trials for Allergan, ATI, Electrocore and Pfizer. ZK has received honoraria as a speaker and/or consultant from Allergan, Bayer, Ely-Lilly, Novartis and TEVA. VO has received honoraria as a speaker and/or consultant from Allergan, Pfizer and Takeda and has conducted clinical trials for Amgen. KP has received honoraria as a speaker and/or consultant, and/or received research support, from Allergan, Amgen/Novartis, Autonomic Technologies Inc., Ely-Lilly and Teva. PM is or has been an Advisory Board member for Allergan, AMGEN, Novartis and TEVA and a Speakers’ Bureau member for ACRAF and Elythrapharma, and has received royalties from Springer and travel support from the European Medicines Agency and SpringerNature.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.